title: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome.
abstract: OBJECTIVE
  To determine the safety, pharmacokinetics, biological effects, and immunogenicity of recombinant soluble complement receptor 1 (TP10) in patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
  
  
  METHODS
  Open label, ascending dosage, phase I trial.
  
  
  METHODS
  Two academic teaching hospitals.
  
  
  METHODS
  A total of 24 patients diagnosed with ALI/ARDS.
  
  
  METHODS
  A single, 30-min intravenous infusion of 0.1, 0.3, 1, 3, or 10 mg/kg TP10.
  
  
  RESULTS
  Serum levels of TP10 increased in proportion to the dose. Mean variable estimates (+/-SD) were half-life of disposition 69.7 +/- 39.7 hrs, plasma clearance 2.39 +/- 1.32 mL/hr/kg, and volume of distribution 190.6 +/- 135.0 mL/kg. Inhibition of complement activity, measured by CH50, was significant for the interaction of dose and time (p = .024). The C3a levels demonstrated a trend for dose which did not reach statistical significance (p = .090) and soluble C5b-9 levels were significant only for dose (p = .023). As expected by the proposed physiologic mechanism, C4a levels were not affected by TP10, dose, or time. The overall mortality rate was 33%. Neither the type nor the frequency rate of specific adverse events were substantially different between dose groups. Seven adverse events in four patients were thought to be possibly related to TP10.
  
  
  CONCLUSIONS
  TP10 has a half-life of approximately 70 hrs and at doses > or =1 mg/kg, significantly inhibits complement activity at the levels of C3 and C5 in patients with ALI/ARDS. Complement inhibition was more prolonged over time with TP10 doses of 3 and 10 mg/kg. TP10 appears to be safe at the doses tested. Further studies will be required to completely assess the impact of TP10 on pathophysiology and clinical outcome in patients with ALI/ARDS.
authors.affiliation: Baylor College of Medicine, Houston, TX, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Zimmerman
authors.forename: R P
authors.initials: RP
authors.lastname: Dellinger
authors.forename: R C
authors.initials: RC
authors.lastname: Straube
authors.forename: J L
authors.initials: JL
authors.lastname: Levin
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood; D003422:Critical Care; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008168:Lung / Q000276:immunology; D055370:Lung Injury; D008297:Male; D008875:Middle Aged; D011951:Receptors, Complement / Q000008:administration & dosage* / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D015996:Survival Rate
chemical_list: D000906:Antibodies; D011951:Receptors, Complement; D011994:Recombinant Proteins